These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 31937586

  • 61. Relationship between type 1 metabotropic glutamate receptors and cerebellar ataxia.
    Ishibashi K, Miura Y, Ishikawa K, Zhang MR, Toyohara J, Ishiwata K, Ishii K.
    J Neurol; 2016 Nov; 263(11):2179-2187. PubMed ID: 27502082
    [Abstract] [Full Text] [Related]

  • 62. Spinocerebellar degenerations--clinical aspects and new treatment of ataxia.
    Sobue I.
    Jpn J Med; 1985 Feb; 24(1):62-7. PubMed ID: 3923240
    [No Abstract] [Full Text] [Related]

  • 63. Structural and functional MRI abnormalities of cerebellar cortex and nuclei in SCA3, SCA6 and Friedreich's ataxia.
    Stefanescu MR, Dohnalek M, Maderwald S, Thürling M, Minnerop M, Beck A, Schlamann M, Diedrichsen J, Ladd ME, Timmann D.
    Brain; 2015 May; 138(Pt 5):1182-97. PubMed ID: 25818870
    [Abstract] [Full Text] [Related]

  • 64. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, Tseng LM, Zhang Q, Shen K, Liu D, Dreosti LM, Burris HA, Toi M, Buyse ME, Cabaribere D, Lindsay MA, Rao S, Pacaud LB, Taran T, Slamon D.
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [Abstract] [Full Text] [Related]

  • 65. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Warren RB, Mrowietz U, von Kiedrowski R, Niesmann J, Wilsmann-Theis D, Ghoreschi K, Zschocke I, Falk TM, Blödorn-Schlicht N, Reich K.
    Lancet; 2017 Feb 04; 389(10068):528-537. PubMed ID: 28012564
    [Abstract] [Full Text] [Related]

  • 66. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
    Vermeire S, Sandborn WJ, Danese S, Hébuterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hinz M, Ahmad A, Pradhan V, Hassan-Zahraee M, Clare R, Cataldi F, Reinisch W.
    Lancet; 2017 Jul 08; 390(10090):135-144. PubMed ID: 28527704
    [Abstract] [Full Text] [Related]

  • 67. Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials.
    Weisler RH, Hirschfeld R, Cutler AJ, Gazda T, Ketter TA, Keck PE, Swann A, Kalali A, SPD417 Study Group.
    CNS Drugs; 2006 Jul 08; 20(3):219-31. PubMed ID: 16529527
    [Abstract] [Full Text] [Related]

  • 68. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
    Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB, PHOENIX 1 study investigators.
    Lancet; 2008 May 17; 371(9625):1665-74. PubMed ID: 18486739
    [Abstract] [Full Text] [Related]

  • 69. A case series of hereditary cerebellar ataxias in a highly consanguineous population from Northeast Brazil.
    Rangel DM, Nóbrega PR, Saraiva-Pereira ML, Jardim LB, Braga-Neto P.
    Parkinsonism Relat Disord; 2019 Apr 17; 61():193-197. PubMed ID: 30389370
    [Abstract] [Full Text] [Related]

  • 70. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
    Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M, SIROCCO study investigators.
    Lancet; 2016 Oct 29; 388(10056):2115-2127. PubMed ID: 27609408
    [Abstract] [Full Text] [Related]

  • 71. Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial.
    Chabriat H, Bassetti CL, Marx U, Audoli-Inthavong ML, Sors A, Lambert E, Wattez M, Hermann DM, RESTORE BRAIN study investigators.
    Lancet Neurol; 2020 Mar 29; 19(3):226-233. PubMed ID: 32085836
    [Abstract] [Full Text] [Related]

  • 72. Frequency analysis of autosomal dominant cerebellar ataxias in Japanese patients and clinical characterization of spinocerebellar ataxia type 6.
    Watanabe H, Tanaka F, Matsumoto M, Doyu M, Ando T, Mitsuma T, Sobue G.
    Clin Genet; 1998 Jan 29; 53(1):13-9. PubMed ID: 9550356
    [Abstract] [Full Text] [Related]

  • 73. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, Nunn A, Cano MG, MacManus D, Miller D, Mallik S, Zajicek J.
    Health Technol Assess; 2015 Feb 29; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [Abstract] [Full Text] [Related]

  • 74. Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.
    Gracies JM, Brashear A, Jech R, McAllister P, Banach M, Valkovic P, Walker H, Marciniak C, Deltombe T, Skoromets A, Khatkova S, Edgley S, Gul F, Catus F, De Fer BB, Vilain C, Picaut P, International AbobotulinumtoxinA Adult Upper Limb Spasticity Study Group.
    Lancet Neurol; 2015 Oct 29; 14(10):992-1001. PubMed ID: 26318836
    [Abstract] [Full Text] [Related]

  • 75. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH.
    Lancet Psychiatry; 2017 Aug 29; 4(8):595-604. PubMed ID: 28668671
    [Abstract] [Full Text] [Related]

  • 76. Mesenchymal Stem Cell Therapy in the Treatment of Neurodegenerative Cerebellar Ataxias: a Systematic Review and Meta-analysis.
    Bhartiya M, Kumar A, Singh RK, Radhakrishnan DM, Rajan R, Srivastava AK.
    Cerebellum; 2023 Jun 29; 22(3):363-369. PubMed ID: 35451803
    [Abstract] [Full Text] [Related]

  • 77. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3.
    Zesiewicz TA, Greenstein PE, Sullivan KL, Wecker L, Miller A, Jahan I, Chen R, Perlman SL.
    Neurology; 2012 Feb 21; 78(8):545-50. PubMed ID: 22323747
    [Abstract] [Full Text] [Related]

  • 78. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, Pedersen KB, Saugstrup T, Meier JJ, PIONEER 4 investigators.
    Lancet; 2019 Jul 06; 394(10192):39-50. PubMed ID: 31186120
    [Abstract] [Full Text] [Related]

  • 79. Evaluation of the effect of thyrotropin releasing hormone (TRH) on regional cerebral blood flow in spinocerebellar degeneration using 3DSRT.
    Kimura N, Kumamoto T, Masuda T, Nomura Y, Hanaoka T, Hazama Y, Okazaki T, Arakawa R.
    J Neurol Sci; 2009 Jun 15; 281(1-2):93-8. PubMed ID: 19286195
    [Abstract] [Full Text] [Related]

  • 80. Double-blind crossover study with physostigmine in patients with degenerative cerebellar diseases.
    Wessel K, Langenberger K, Nitschke MF, Kömpf D.
    Arch Neurol; 1997 Apr 15; 54(4):397-400. PubMed ID: 9109740
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.